Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient

ABSTRACT For the first time the glycosylation of a patient with a MPI‐CDG during pregnancy is monitored. MPI‐CDG, is characterised by a deficiency in mannose‐6‐phosphate isomerase (MPI) leading to a reduced pool of glycosylation precursors, impairing the biosynthesis of N‐glycans leading to N‐glycos...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elodie Lebredonchel, Sandrine Duvet, Claire Douillard, François Foulquier, André Klein
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
CDG
MPI
Acceso en línea:https://doaj.org/article/ead49bbddb1644f689b4f75152da451e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ead49bbddb1644f689b4f75152da451e
record_format dspace
spelling oai:doaj.org-article:ead49bbddb1644f689b4f75152da451e2021-11-08T13:27:18ZVariation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient2192-831210.1002/jmd2.12247https://doaj.org/article/ead49bbddb1644f689b4f75152da451e2021-11-01T00:00:00Zhttps://doi.org/10.1002/jmd2.12247https://doaj.org/toc/2192-8312ABSTRACT For the first time the glycosylation of a patient with a MPI‐CDG during pregnancy is monitored. MPI‐CDG, is characterised by a deficiency in mannose‐6‐phosphate isomerase (MPI) leading to a reduced pool of glycosylation precursors, impairing the biosynthesis of N‐glycans leading to N‐glycosylation defects. The abnormal N‐glycosylation profile with an elevation of asialotransferrin and disialotransferrin, typical of CDG type I, is assessable by transferrin isoelectrofocusing. Oral D‐mannose supplementation for MPI‐CDG patients has been widely used and improves clinical manifestations. The glycosylation of a MPI‐CDG patient during pregnancy without mannose supplementation was studied using carbohydrate deficient transferrin (CDT) assay, transferrin isoelectrofocusing (IEF) and mass spectrometry of total serum N‐glycans. A general improvement of the glycosylation profile of the patient due to a better transfer of the glycan precursors as well as an increase of the triantennary glycans (and sialylation) was observed. In conclusion, in the absence of mannose supplementation, the previously observed glycosylation abnormality of the MPI‐CDG patient was corrected. The molecular mechanism underlying this N‐glycosylation rescue during MPI‐CDG pregnancy further needs to be investigated.Elodie LebredonchelSandrine DuvetClaire DouillardFrançois FoulquierAndré KleinWileyarticleCDGglycosylationmannoseMPIpregnancytransferrinDiseases of the endocrine glands. Clinical endocrinologyRC648-665GeneticsQH426-470ENJIMD Reports, Vol 62, Iss 1, Pp 22-29 (2021)
institution DOAJ
collection DOAJ
language EN
topic CDG
glycosylation
mannose
MPI
pregnancy
transferrin
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Genetics
QH426-470
spellingShingle CDG
glycosylation
mannose
MPI
pregnancy
transferrin
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Genetics
QH426-470
Elodie Lebredonchel
Sandrine Duvet
Claire Douillard
François Foulquier
André Klein
Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
description ABSTRACT For the first time the glycosylation of a patient with a MPI‐CDG during pregnancy is monitored. MPI‐CDG, is characterised by a deficiency in mannose‐6‐phosphate isomerase (MPI) leading to a reduced pool of glycosylation precursors, impairing the biosynthesis of N‐glycans leading to N‐glycosylation defects. The abnormal N‐glycosylation profile with an elevation of asialotransferrin and disialotransferrin, typical of CDG type I, is assessable by transferrin isoelectrofocusing. Oral D‐mannose supplementation for MPI‐CDG patients has been widely used and improves clinical manifestations. The glycosylation of a MPI‐CDG patient during pregnancy without mannose supplementation was studied using carbohydrate deficient transferrin (CDT) assay, transferrin isoelectrofocusing (IEF) and mass spectrometry of total serum N‐glycans. A general improvement of the glycosylation profile of the patient due to a better transfer of the glycan precursors as well as an increase of the triantennary glycans (and sialylation) was observed. In conclusion, in the absence of mannose supplementation, the previously observed glycosylation abnormality of the MPI‐CDG patient was corrected. The molecular mechanism underlying this N‐glycosylation rescue during MPI‐CDG pregnancy further needs to be investigated.
format article
author Elodie Lebredonchel
Sandrine Duvet
Claire Douillard
François Foulquier
André Klein
author_facet Elodie Lebredonchel
Sandrine Duvet
Claire Douillard
François Foulquier
André Klein
author_sort Elodie Lebredonchel
title Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
title_short Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
title_full Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
title_fullStr Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
title_full_unstemmed Variation of the serum N‐glycosylation during the pregnancy of a MPI‐CDG patient
title_sort variation of the serum n‐glycosylation during the pregnancy of a mpi‐cdg patient
publisher Wiley
publishDate 2021
url https://doaj.org/article/ead49bbddb1644f689b4f75152da451e
work_keys_str_mv AT elodielebredonchel variationoftheserumnglycosylationduringthepregnancyofampicdgpatient
AT sandrineduvet variationoftheserumnglycosylationduringthepregnancyofampicdgpatient
AT clairedouillard variationoftheserumnglycosylationduringthepregnancyofampicdgpatient
AT francoisfoulquier variationoftheserumnglycosylationduringthepregnancyofampicdgpatient
AT andreklein variationoftheserumnglycosylationduringthepregnancyofampicdgpatient
_version_ 1718442290752520192